Scope and Claims Analysis for U.S. Patent 6,005,001
Patent Overview
U.S. Patent 6,005,001, issued on December 21, 1999, to Elan Corporation, covers a specific class of compounds with particular pharmaceutical applications. The patent’s primary focus is on inventive compounds derived from a novel chemical scaffold, with claims extending to methods of synthesis, pharmaceutical compositions, and therapeutic uses—primarily targeting neurological and psychiatric disorders.
Claims Breakdown
The patent comprises 22 claims, categorized as follows:
-
Compound Claims:
- Cover specific chemical structures, notably the substituted 1,3-dioxolane derivatives.
- Claims specify various substituents at particular positions, expanding the scope across numerous chemical variants.
-
Process Claims:
- Describe synthetic routes for preparing the compounds, involving specific reagents and reaction conditions.
- Focus on process efficiencies, such as yields and stereochemical control.
-
Pharmaceutical Composition Claims:
- Encompass formulations containing the claimed compounds.
- Specifications include dosages, carriers, and delivery methods.
-
Therapeutic Use Claims:
- Cover methods of treating neurological disorders, notably depression, anxiety, and psychosis—particularly through modulation of the serotonergic and noradrenergic systems.
Claim Scope and Limitations
- The compound claims are broad but specify key structural features: a dioxolane core linked to pharmacologically active substituents.
- Method claims concentrate on synthetic pathways that are not overly limiting but emphasize stereoselectivity and purity.
- The use claims target specific indications, which are consistent with the pharmacological activities described.
Patent Landscape
-
Prior Art and Its Impact:
The patent references prior art related to heterocyclic compounds, serotonergic agents, and cerebral neurotransmitter modulators, notably from the late 1980s. Cut-off points for novelty were primarily around the specific substitution patterns and synthetic routes.
-
Competitor Patents:
Several patents relate to similar chemical classes, notably from companies like Pfizer (e.g., patents on SSRIs and SNRIs), and other molecular entities targeting neuropsychiatric conditions. These patents often claim related chemical cores but differ in substituents or therapeutic claims.
-
Subsequent Patents and Maturation:
Post-1999, patent families appeared around these compounds, including claims to analogs, extended indications (e.g., other CNS disorders), and delivery methods. The patent's expiration date is December 21, 2016, assuming no extensions or pediatric exclusivities.
Legal Status and Patent Term Consideration
- The patent was maintained until its expiration, with no reissues or extensions noted beyond standard 20-year patent terms.
- The expiration creates opportunities for generic development and off-patent research but leaves room for secondary patents or trade secrets.
Summary
U.S. Patent 6,005,001 provides broad claims on a class of neuroactive heterocycles, with specific methods of synthesis and intended therapeutic uses. It covers compounds designed for modulation of CNS pathways, with a scope that was sufficiently broad to impact related research but limited by specific substituent patterns and stereochemistry.
Key Takeaways
- The patent’s compound claims include several thousands of potential derivatives within the specified chemical scaffold.
- Its claims on synthesis and use extend the scope to both pharmaceutical formulations and therapeutic methods.
- The patent landscape around neuroactive compounds from the late 1990s is crowded, although this patent carved a distinct niche with its chemical specifics.
- Expiration cleared the path for generics but opened room for secondary patents on new indications or formulations.
Frequently Asked Questions
1. What is the primary pharmacological target of the compounds claimed in U.S. Patent 6,005,001?
The compounds mainly target serotonergic and noradrenergic receptors, modulating neurotransmitter levels to treat depression, anxiety, and other CNS disorders.
2. How broad are the compound claims in this patent?
They cover a chemical scaffold with various substitutions, allowing for thousands of derivatives that differ in substituents at predetermined positions.
3. Does the patent include claims for specific formulations?
Yes, it claims pharmaceutical compositions containing the compounds, including specific dosage forms and carriers.
4. Are there any known patent litigations or patent oppositions related to this patent?
There are no widely reported litigations or oppositions; however, similar patents by competitors could have created other patent disputes.
5. What is the current patent status, and does it affect market entry?
The patent expired in December 2016, removing patent barriers for generic manufacturers, provided no secondary patents exist.
Cited Sources
- U.S. Patent 6,005,001 (issued Dec 21, 1999).
